Disease Overview：AL amyloidosis of the kidney（AL amyloidosis）
AL amyloidosis is a systemic plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains—predominantly lambda or kappa—in renal glomeruli, tubules, and interstitium. This leads to progressive proteinuria, nephrotic syndrome, and eventual chronic kidney disease or end-stage renal failure. Diagnosis requires tissue biopsy (typically renal or abdominal fat pad) with Congo red staining demonstrating apple-green birefringence under polarized light, confirmed by mass spectrometry or immunohistochemistry for light-chain restriction. Prognosis hinges on early detection and timely initiation of hematologic therapy targeting the underlying clonal plasma cells—common regimens include bortezomib-based combinations (e.g., CyBorD), daratumumab-containing protocols, or high-dose melphalan with autologous stem cell transplantation in eligible patients. Renal involvement significantly worsens survival; median overall survival without treatment is less than 12 months, underscoring the need for multidisciplinary care integrating nephrology, hematology, and supportive management.
China offers distinct advantages for AL amyloidosis treatment: leading academic hospitals—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—host specialized amyloidosis centers with internationally trained hematologists and nephrologists experienced in complex multi-organ staging and risk-adapted therapy. Advanced diagnostics—including serum free light chain assays, cardiac MRI with T1 mapping, and next-generation sequencing—are widely available. Clinical outcomes align with global benchmarks: recent multicenter data report ≥60% hematologic response rates and improved renal function stabilization in over 40% of treated patients. Treatment 40–60% lower than in the US or Western Europe, without compromising evidence-based standards. As a dedicated medical tourism agency, we facilitate seamless international patient access—handling hospital referrals and therapeutic planning, providing transparent, all-inclusive pricing, and delivering end-to-end support from visa assistance to post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: AL Amyloidosis (Renal)
Non-Surgical / Conservative / Medication Options
*Target Criteria:* Newly diagnosed, low-to-intermediate cardiac involvement (NT-proBNP < 1,800 pg/mL, troponin T < 0.05 ng/mL), eGFR ≥30 mL/min/1.73m², no dialysis dependence.
- •First-Line Chemotherapy (Bortezomib + Cyclophosphamide + Dexamethasone – CyBorD)
• Bortezomib (IV, 1.3 mg/m² × 8 doses): $1,620 • Cyclophosphamide (oral, 500 mg/day × 90 days): $180 • Dexamethasone (oral, 20 mg × 4 days/cycle × 4 cycles): $60 - Monitoring labs (CBC, renal panel, serum free light chains, NT-proBNP, troponin × 8 visits): $420 - Renal ultrasound + Doppler (baseline + 3-month): $180
- •Second-Line (Daratumumab-based regimens)
- Infusion nursing + premedication (dexamethasone, antihistamines): $1,100 - Mandatory serum/plasma cell studies (bone marrow biopsy, flow cytometry, FISH): $1,350
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Dialysis-dependent (eGFR <15), stable cardiac function (LVEF ≥45%, no NYHA Class III–IV HF), absence of active infection or uncontrolled hypertension.
- •Autologous Stem Cell Transplant (ASCT)
- Mobilization (G-CSF × 5 days + apheresis × 2 sessions): $1,750 - High-dose Melphalan conditioning + inpatient ASCT admission (21-day stay, ICU-capable ward): $18,600–$21,400 - Post-transplant monitoring (engraftment labs, infection prophylaxis, renal function tracking × 12 weeks): $2,300
Special / Complex Condition Options
- •Dialysis-Dependent Patients with Cardiac Amyloidosis:
- Ultrafiltration-controlled HD + extended-duration sessions: +$2,100/year
- •Refractory Proteinuria (>5 g/day) with Nephrotic Syndrome:
- Albumin infusions (25% × 12 doses): $1,050
Quick Selection Guide
- •Age <65, eGFR ≥45, no cardiac involvement: Start CyBorD ($3,400 total year-1); optimal balance of efficacy and cost.
- •Age 65–75, eGFR 15–30, mild cardiac biomarker elevation: Prefer Daratumumab monotherapy ($15,300 year-1); avoids ASCT toxicity.
- •Age <60, dialysis-dependent, LVEF ≥50%: Pursue ASCT ($27,500 total); only curative-intent option with proven OS benefit.
- •Budget-constrained (<$5,000), elderly (>75), multiorgan failure: Supportive care + low-dose dexamethasone + ACEi/ARB ($1,200 year-1); focuses on symptom control and edema management.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended AL amyloidosis of the kidney Medical Vacation Packages
Curated transparent all-inclusive packages combining AL amyloidosis of the kidney treatment with China top medical destinations:
